CEVEC signs agreement with Roche for the use of CEVEC’s ELEVECTA® Technology in gene therapy

  • Agreement will allow Roche to use CEVEC’s unique and proprietary ELEVECTA® Technology
    for AAV vector manufacturing
  • The ELEVECTA® Stable Producer Cell Lines are designed to enable fully scalable, high-performance AAV vector production in suspension bioprocesses widely used in the biopharmaceutical industry

Cologne, Germany, November 10, 2020


Subscribe for the CEVEC Newsletter according to our Privacy Policy to receive the latest CEVEC News, including Press Releases, Conference Information and Webinar Invitations.

© CEVEC Pharmaceuticals GmbH 2020